<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00247273</url>
  </required_header>
  <id_info>
    <org_study_id>2005032</org_study_id>
    <secondary_id>EFC6062 AND HMRF004M/3001</secondary_id>
    <nct_id>NCT00247273</nct_id>
  </id_info>
  <brief_title>A Study of Monthly Risedronate for Osteoporosis</brief_title>
  <official_title>A Phase III, Multicenter, Double-blind, Randomized, Active-controlled, Parallel Group, Non-inferiority Study Comparing 150 mg Risedronate Monthly With 5 mg Risedronate Daily in the Treatment of Postmenopausal Osteoporosis (PMO)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Warner Chilcott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Warner Chilcott</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to study the efficacy of a single-dose monthly dosing regimen as
      compared to the standard daily dosing regimen of risedronate 5 mg daily.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The comparator arms of this risedronate study are 150 mg monthly and 5 mg daily.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2005</start_date>
  <completion_date type="Actual">April 2008</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change From Baseline in Lumbar Spine Bone Mineral Density (BMD) at Month 12-Endpoint in Women With Postmenopausal Osteoporosis, Primary Efficacy Population</measure>
    <time_frame>Baseline to Month 12 - Endpoint</time_frame>
    <description>BMD assessed using dual-energy x-ray absorptiometry (DXA) using Hologic or Lunar equipment. LOCF - last observation carried forward (Last post-baseline measurement available to Month 12).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Lumbar Spine BMD at Month 12, ITT Population</measure>
    <time_frame>Baseline to Month 12</time_frame>
    <description>BMD assessed using dual-energy x-ray absorptiometry (DXA) using Hologic or Lunar equipment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Lumbar Spine BMD at Month 12, ITT Population</measure>
    <time_frame>Baseline to Month 12</time_frame>
    <description>BMD assessed using dual-energy x-ray absorptiometry (DXA) using Hologic or Lunar equipment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Lumbar Spine BMD at Month 24-Endpoint, Endpoint Population (Month 24)</measure>
    <time_frame>Baseline to Month 24 - Endpoint</time_frame>
    <description>BMD assessed using dual-energy x-ray absorptiometry (DXA) using Hologic or Lunar equipment. LOCF - last observation carried forward (Last post-baseline measurement available to Month 24).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Lumbar Spine BMD at Month 24, ITT Population</measure>
    <time_frame>Baseline to Month 24</time_frame>
    <description>BMD assessed using dual-energy x-ray absorptiometry (DXA) using Hologic or Lunar equipment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Lumbar Spine BMD at Month 24, ITT Population</measure>
    <time_frame>Baseline to Month 24</time_frame>
    <description>BMD assessed using dual-energy x-ray absorptiometry (DXA) using Hologic or Lunar equipment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Urine Type-1 Collagen Cross-linked-N-telopeptide Corrected for Creatinine Clearance (NTX/Cr) at Month 6, ITT Population</measure>
    <time_frame>Baseline to Month 6</time_frame>
    <description>Assayed by ELISA (enzyme-linked immunosorbent assay) for NTX and colorimetric assay for creatinine. Patient collected second urine voided between 6 and 9 am from day of clinic visit and day before clinic visit at Months 3, 6, 12 &amp; 24. nmol BCE / mmol Creatinine = nanomoles bone collagen equivalents / millimoles Creatinine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Urine NTX/Cr at Month 6, ITT Population</measure>
    <time_frame>Baseline to Month 6</time_frame>
    <description>Assayed by ELISA (enzyme-linked immunosorbent assay) for NTX and colorimetric assay for creatinine. Patient collected second urine voided between 6 and 9 am from day of clinic visit and day before clinic visit at Months 3, 6, 12 &amp; 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Urine NTX/Cr at Month 24, ITT Population</measure>
    <time_frame>Baseline to Month 24</time_frame>
    <description>Assayed by ELISA (enzyme-linked immunosorbent assay) for NTX and colorimetric assay for creatinine. Patient collected second urine voided between 6 and 9 am from day of clinic visit and day before clinic visit at Months 3, 6, 12 &amp; 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Urine NTX/Cr at Month 24, ITT Population</measure>
    <time_frame>Baseline to Month 24</time_frame>
    <description>Assayed by ELISA (enzyme-linked immunosorbent assay) for NTX and colorimetric assay for creatinine. Patient collected second urine voided between 6 and 9 am from day of clinic visit and day before clinic visit at Months 3, 6, 12 &amp; 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Serum Type-1 Collagen Cross-linked C-telopeptide (CTX) at Month 6, ITT Population</measure>
    <time_frame>Baseline to Month 6</time_frame>
    <description>ng / mL = nanograms / milliliter. Assayed by electrochemiluminescent immunoassay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Serum CTX at Month 6, ITT Population</measure>
    <time_frame>Baseline to Month 6</time_frame>
    <description>Assayed by electrochemiluminescent immunoassay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Serum CTX at Month 24, ITT Population</measure>
    <time_frame>Baseline to Month 24</time_frame>
    <description>Assayed by electrochemiluminescent immunoassay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Serum CTX at Month 24, ITT Population</measure>
    <time_frame>Baseline to Month 24</time_frame>
    <description>Assayed by electrochemiluminescent immunoassay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Serum Bone-specific Alkaline Phosphatase (BAP) at Month 6, ITT Population</measure>
    <time_frame>Baseline to Month 6</time_frame>
    <description>ug / L = micrograms per liter, Assayed by ELISA (enzyme-linked immunosorbent assay)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Serum BAP at Month 6, ITT Population</measure>
    <time_frame>Baseline to Month 6</time_frame>
    <description>Assayed by ELISA (enzyme-linked immunosorbent assay)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Serum BAP at Month 24, ITT Population</measure>
    <time_frame>Baseline to Month 24</time_frame>
    <description>Assayed by ELISA (enzyme-linked immunosorbent assay)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Serum BAP at Month 24, ITT Population</measure>
    <time_frame>Baseline to Month 24</time_frame>
    <description>Assayed by ELISA (enzyme-linked immunosorbent assay)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With New Vertebral Fracture at Month 12, ITT Population</measure>
    <time_frame>Baseline to Month 12</time_frame>
    <description>At least 1 new fractured vertebra</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With New Vertebral Fracture at Month 24, ITT Population</measure>
    <time_frame>Baseline to Month 24</time_frame>
    <description>At least 1 new fractured vertebra</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1294</enrollment>
  <condition>Postmenopausal Osteoporosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>5 mg risedronate, once daily for 2 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>150 mg risedronate taken once a month for 2 years</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>risedronate</intervention_name>
    <description>tablet, 5 mg risedronate, once a day for 2 years</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>risedronate</intervention_name>
    <description>oral, 150 mg risedronate, once a month for 2 years</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female: 50 years of age or older

          -  &gt;5 years since last menses natural or surgical

          -  have lumbar spine BMD (bone mineral density) more that 2.5 standard deviations (SD)
             below the young adult mean, or have 1-spine BMD more than 2.0 SD below the young adult
             female mean value and also have at least one prevalent vertebral body fracture

        Exclusion Criteria:

          -  history of uncontrolled hyperparathyroidism, hyperthyroidism, osteomalacia

          -  BMI (body mass index) &gt;32 kg/m^2

          -  use of medications within 3 months of starting study drug that impact bone metabolism
             such as glucocorticoids, estrogens, calcitonin, calcitriol, other bisphosphonates and
             parathyroid hormone

          -  hypocalcemia or hypercalcemia of any cause

          -  markedly abnormal clinical laboratory measurements that are assessed as clinically
             significant by the investigator
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sal Bartelmo, MD</last_name>
    <role>Study Director</role>
    <affiliation>P&amp;G</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lakewood</city>
        <state>Colorado</state>
        <zip>80227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gainesville</city>
        <state>Georgia</state>
        <zip>30501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>068131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>West Haverstraw</city>
        <state>New York</state>
        <zip>10983</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Capital Federal</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Geelong</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Heidelberg, Victoria</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint Leonards</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Liege</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mont Godinne</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rio de Janeiro</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Calgary</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Montreal</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sainte Foy</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saskatoon</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Parnu</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tartu</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kuopio</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oulu</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Turku</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Amiens Cedex 1</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lyon Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Orleans</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vandoeuvre Les Nancy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Balatonfured</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gyor</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miskolc</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nagykanizs</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Beirut</city>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Paradis</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Trondheim</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bialystok</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Granada</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Estonia</country>
    <country>Finland</country>
    <country>France</country>
    <country>Hungary</country>
    <country>Lebanon</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 28, 2005</study_first_submitted>
  <study_first_submitted_qc>October 28, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 1, 2005</study_first_posted>
  <results_first_submitted>March 4, 2011</results_first_submitted>
  <results_first_submitted_qc>May 23, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 21, 2011</results_first_posted>
  <last_update_submitted>April 15, 2013</last_update_submitted>
  <last_update_submitted_qc>April 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 22, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>randomized controlled trial, osteoporosis, risedronate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Osteoporosis, Postmenopausal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Risedronate Sodium</mesh_term>
    <mesh_term>Etidronic Acid</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Screening period began 17 Oct '05</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>5 mg Risedronate</title>
          <description>5 mg risedronate tablet, once daily for 2 years</description>
        </group>
        <group group_id="P2">
          <title>150 mg Risedronate</title>
          <description>150 mg risedronate taken once a month for 2 years</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="644"/>
                <participants group_id="P2" count="650"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Intent to Treat Population</title>
              <participants_list>
                <participants group_id="P1" count="642">Two subjects not included as they did not take any study medication.</participants>
                <participants group_id="P2" count="650"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="498"/>
                <participants group_id="P2" count="513"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="146"/>
                <participants group_id="P2" count="137"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="85"/>
                <participants group_id="P2" count="80"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="47"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did not take any study drug</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>5 mg Risedronate</title>
          <description>5 mg risedronate tablet, once daily for 2 years</description>
        </group>
        <group group_id="B2">
          <title>150 mg Risedronate</title>
          <description>150 mg risedronate taken once a month for 2 years</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="644"/>
            <count group_id="B2" value="650"/>
            <count group_id="B3" value="1294"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>ITT (intent to treat) Population</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.4" spread="7.7"/>
                    <measurement group_id="B2" value="65.5" spread="7.2"/>
                    <measurement group_id="B3" value="64.9" spread="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <description>ITT Population</description>
          <units>Partcipants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt; 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="335"/>
                    <measurement group_id="B2" value="304"/>
                    <measurement group_id="B3" value="639"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>65 - &lt;75 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="232"/>
                    <measurement group_id="B2" value="268"/>
                    <measurement group_id="B3" value="500"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt; = 75 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75"/>
                    <measurement group_id="B2" value="78"/>
                    <measurement group_id="B3" value="153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="644"/>
                    <measurement group_id="B2" value="650"/>
                    <measurement group_id="B3" value="1294"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <description>ITT Population</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Argentina</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="302"/>
                    <measurement group_id="B2" value="304"/>
                    <measurement group_id="B3" value="606"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Belgium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Estonia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Finland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hungary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lebanon</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Norway</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="103"/>
                    <measurement group_id="B2" value="104"/>
                    <measurement group_id="B3" value="207"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change From Baseline in Lumbar Spine Bone Mineral Density (BMD) at Month 12-Endpoint in Women With Postmenopausal Osteoporosis, Primary Efficacy Population</title>
        <description>BMD assessed using dual-energy x-ray absorptiometry (DXA) using Hologic or Lunar equipment. LOCF - last observation carried forward (Last post-baseline measurement available to Month 12).</description>
        <time_frame>Baseline to Month 12 - Endpoint</time_frame>
        <population>ITT (intent to treat) Population</population>
        <group_list>
          <group group_id="O1">
            <title>5 mg Risedronate</title>
            <description>5 mg risedronate tablet, once daily for 2 years</description>
          </group>
          <group group_id="O2">
            <title>150 mg Risedronate</title>
            <description>150 mg risedronate taken once a month for 2 years</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Lumbar Spine Bone Mineral Density (BMD) at Month 12-Endpoint in Women With Postmenopausal Osteoporosis, Primary Efficacy Population</title>
          <description>BMD assessed using dual-energy x-ray absorptiometry (DXA) using Hologic or Lunar equipment. LOCF - last observation carried forward (Last post-baseline measurement available to Month 12).</description>
          <population>ITT (intent to treat) Population</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="642"/>
                <count group_id="O2" value="650"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.425" lower_limit="3.028" upper_limit="3.823"/>
                    <measurement group_id="O2" value="3.540" lower_limit="3.147" upper_limit="3.934"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>In order to establish noninferiority for the primary efficacy variable at one-sided α of 2.5% with 90% power, a total of 1068 patients, 534 per treatment group, is required. This calculation is based on the following assumptions: the noninferiority margin (or delta) = 1.5%, the common SD (standard deviation) of the percent change from baseline in lumbar spine BMD at Month 12 = 4.5%, the 1 year dropout rate = 20%, and the true mean difference μD - μM = 0.5%.</non_inferiority_desc>
            <param_type>Least Square (LS) Mean Difference</param_type>
            <param_value>-0.115</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.505</ci_lower_limit>
            <ci_upper_limit>0.274</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Lumbar Spine BMD at Month 12, ITT Population</title>
        <description>BMD assessed using dual-energy x-ray absorptiometry (DXA) using Hologic or Lunar equipment.</description>
        <time_frame>Baseline to Month 12</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>5 mg Risedronate</title>
            <description>5 mg risedronate tablet, once daily for 2 years</description>
          </group>
          <group group_id="O2">
            <title>150 mg Risedronate</title>
            <description>150 mg risedronate taken once a month for 2 years</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Lumbar Spine BMD at Month 12, ITT Population</title>
          <description>BMD assessed using dual-energy x-ray absorptiometry (DXA) using Hologic or Lunar equipment.</description>
          <population>ITT Population</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="642"/>
                <count group_id="O2" value="650"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.522" lower_limit="3.116" upper_limit="3.928"/>
                    <measurement group_id="O2" value="3.598" lower_limit="3.201" upper_limit="3.995"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.076</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.475</ci_lower_limit>
            <ci_upper_limit>0.323</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Lumbar Spine BMD at Month 12, ITT Population</title>
        <description>BMD assessed using dual-energy x-ray absorptiometry (DXA) using Hologic or Lunar equipment.</description>
        <time_frame>Baseline to Month 12</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>5 mg Risedronate</title>
            <description>5 mg risedronate tablet, once daily for 2 years</description>
          </group>
          <group group_id="O2">
            <title>150 mg Risedronate</title>
            <description>150 mg risedronate taken once a month for 2 years</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Lumbar Spine BMD at Month 12, ITT Population</title>
          <description>BMD assessed using dual-energy x-ray absorptiometry (DXA) using Hologic or Lunar equipment.</description>
          <population>ITT</population>
          <units>g/cm^2</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="642"/>
                <count group_id="O2" value="650"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0256" lower_limit="0.0226" upper_limit="0.0286"/>
                    <measurement group_id="O2" value="0.0261" lower_limit="0.0232" upper_limit="0.0291"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.0005</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.0035</ci_lower_limit>
            <ci_upper_limit>0.0024</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Lumbar Spine BMD at Month 24-Endpoint, Endpoint Population (Month 24)</title>
        <description>BMD assessed using dual-energy x-ray absorptiometry (DXA) using Hologic or Lunar equipment. LOCF - last observation carried forward (Last post-baseline measurement available to Month 24).</description>
        <time_frame>Baseline to Month 24 - Endpoint</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>5 mg Risedronate</title>
            <description>5 mg risedronate tablet, once daily for 2 years</description>
          </group>
          <group group_id="O2">
            <title>150 mg Risedronate</title>
            <description>150 mg risedronate taken once a month for 2 years</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Lumbar Spine BMD at Month 24-Endpoint, Endpoint Population (Month 24)</title>
          <description>BMD assessed using dual-energy x-ray absorptiometry (DXA) using Hologic or Lunar equipment. LOCF - last observation carried forward (Last post-baseline measurement available to Month 24).</description>
          <population>ITT Population</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="642"/>
                <count group_id="O2" value="650"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.927" lower_limit="3.432" upper_limit="4.422"/>
                    <measurement group_id="O2" value="4.166" lower_limit="3.677" upper_limit="4.654"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The sample size of 1068 patients will provide approximately 90% power to demonstrate the noninferiority of the monthly regimen at month 24, using a 2% noninferiority margin and assuming a common SD of the percent change from baseline in lumbar spine BMD at month 24 of 5%, a 2-year dropout rate of 30%, and a true mean difference (uDaily-uMonthly) of 0.8%.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The estimates of the common SD, dropout rate at month 24 and true difference are also based on previous risedronate Phase III studies (RVN008993, RVE009093, ROE009394, HMR4003E/3001).</non_inferiority_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.239</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.727</ci_lower_limit>
            <ci_upper_limit>0.249</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Lumbar Spine BMD at Month 24, ITT Population</title>
        <description>BMD assessed using dual-energy x-ray absorptiometry (DXA) using Hologic or Lunar equipment.</description>
        <time_frame>Baseline to Month 24</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>5 mg Risedronate</title>
            <description>5 mg risedronate tablet, once daily for 2 years</description>
          </group>
          <group group_id="O2">
            <title>150 mg Risedronate</title>
            <description>150 mg risedronate taken once a month for 2 years</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Lumbar Spine BMD at Month 24, ITT Population</title>
          <description>BMD assessed using dual-energy x-ray absorptiometry (DXA) using Hologic or Lunar equipment.</description>
          <population>ITT</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="642"/>
                <count group_id="O2" value="650"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.217" lower_limit="3.685" upper_limit="4.750"/>
                    <measurement group_id="O2" value="4.302" lower_limit="3.783" upper_limit="4.822"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.085</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.609</ci_lower_limit>
            <ci_upper_limit>0.439</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Lumbar Spine BMD at Month 24, ITT Population</title>
        <description>BMD assessed using dual-energy x-ray absorptiometry (DXA) using Hologic or Lunar equipment.</description>
        <time_frame>Baseline to Month 24</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>5 mg Risedronate</title>
            <description>5 mg risedronate tablet, once daily for 2 years</description>
          </group>
          <group group_id="O2">
            <title>150 mg Risedronate</title>
            <description>150 mg risedronate taken once a month for 2 years</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Lumbar Spine BMD at Month 24, ITT Population</title>
          <description>BMD assessed using dual-energy x-ray absorptiometry (DXA) using Hologic or Lunar equipment.</description>
          <population>ITT</population>
          <units>g/cm^2</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="642"/>
                <count group_id="O2" value="650"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0309" lower_limit="0.0270" upper_limit="0.0349"/>
                    <measurement group_id="O2" value="0.0319" lower_limit="0.0280" upper_limit="0.0357"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.0009</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.0048</ci_lower_limit>
            <ci_upper_limit>0.0029</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Urine Type-1 Collagen Cross-linked-N-telopeptide Corrected for Creatinine Clearance (NTX/Cr) at Month 6, ITT Population</title>
        <description>Assayed by ELISA (enzyme-linked immunosorbent assay) for NTX and colorimetric assay for creatinine. Patient collected second urine voided between 6 and 9 am from day of clinic visit and day before clinic visit at Months 3, 6, 12 &amp; 24. nmol BCE / mmol Creatinine = nanomoles bone collagen equivalents / millimoles Creatinine</description>
        <time_frame>Baseline to Month 6</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>5 mg Risedronate</title>
            <description>5 mg risedronate tablet, once daily for 2 years</description>
          </group>
          <group group_id="O2">
            <title>150 mg Risedronate</title>
            <description>150 mg risedronate taken once a month for 2 years</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Urine Type-1 Collagen Cross-linked-N-telopeptide Corrected for Creatinine Clearance (NTX/Cr) at Month 6, ITT Population</title>
          <description>Assayed by ELISA (enzyme-linked immunosorbent assay) for NTX and colorimetric assay for creatinine. Patient collected second urine voided between 6 and 9 am from day of clinic visit and day before clinic visit at Months 3, 6, 12 &amp; 24. nmol BCE / mmol Creatinine = nanomoles bone collagen equivalents / millimoles Creatinine</description>
          <population>ITT</population>
          <units>nmol BCE / mmol Creatinine</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="642"/>
                <count group_id="O2" value="650"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-30.04" lower_limit="-33.19" upper_limit="-26.88"/>
                    <measurement group_id="O2" value="-30.26" lower_limit="-33.41" upper_limit="-27.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.23</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.83</ci_lower_limit>
            <ci_upper_limit>3.28</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Urine NTX/Cr at Month 6, ITT Population</title>
        <description>Assayed by ELISA (enzyme-linked immunosorbent assay) for NTX and colorimetric assay for creatinine. Patient collected second urine voided between 6 and 9 am from day of clinic visit and day before clinic visit at Months 3, 6, 12 &amp; 24.</description>
        <time_frame>Baseline to Month 6</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>5 mg Risedronate</title>
            <description>5 mg risedronate tablet, once daily for 2 years</description>
          </group>
          <group group_id="O2">
            <title>150 mg Risedronate</title>
            <description>150 mg risedronate taken once a month for 2 years</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Urine NTX/Cr at Month 6, ITT Population</title>
          <description>Assayed by ELISA (enzyme-linked immunosorbent assay) for NTX and colorimetric assay for creatinine. Patient collected second urine voided between 6 and 9 am from day of clinic visit and day before clinic visit at Months 3, 6, 12 &amp; 24.</description>
          <population>ITT</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="642"/>
                <count group_id="O2" value="650"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-51.83" lower_limit="-54.83" upper_limit="-48.83"/>
                    <measurement group_id="O2" value="-50.26" lower_limit="-53.25" upper_limit="-47.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.57</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.47</ci_lower_limit>
            <ci_upper_limit>1.33</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Urine NTX/Cr at Month 24, ITT Population</title>
        <description>Assayed by ELISA (enzyme-linked immunosorbent assay) for NTX and colorimetric assay for creatinine. Patient collected second urine voided between 6 and 9 am from day of clinic visit and day before clinic visit at Months 3, 6, 12 &amp; 24.</description>
        <time_frame>Baseline to Month 24</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>5 mg Risedronate</title>
            <description>5 mg risedronate tablet, once daily for 2 years</description>
          </group>
          <group group_id="O2">
            <title>150 mg Risedronate</title>
            <description>150 mg risedronate taken once a month for 2 years</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Urine NTX/Cr at Month 24, ITT Population</title>
          <description>Assayed by ELISA (enzyme-linked immunosorbent assay) for NTX and colorimetric assay for creatinine. Patient collected second urine voided between 6 and 9 am from day of clinic visit and day before clinic visit at Months 3, 6, 12 &amp; 24.</description>
          <population>ITT</population>
          <units>nmol BCE / mmol Creatinine</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="642"/>
                <count group_id="O2" value="650"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.88" lower_limit="-32.50" upper_limit="-25.26"/>
                    <measurement group_id="O2" value="-29.87" lower_limit="-33.38" upper_limit="-26.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.54</ci_lower_limit>
            <ci_upper_limit>4.53</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Urine NTX/Cr at Month 24, ITT Population</title>
        <description>Assayed by ELISA (enzyme-linked immunosorbent assay) for NTX and colorimetric assay for creatinine. Patient collected second urine voided between 6 and 9 am from day of clinic visit and day before clinic visit at Months 3, 6, 12 &amp; 24.</description>
        <time_frame>Baseline to Month 24</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>5 mg Risedronate</title>
            <description>5 mg risedronate tablet, once daily for 2 years</description>
          </group>
          <group group_id="O2">
            <title>150 mg Risedronate</title>
            <description>150 mg risedronate taken once a month for 2 years</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Urine NTX/Cr at Month 24, ITT Population</title>
          <description>Assayed by ELISA (enzyme-linked immunosorbent assay) for NTX and colorimetric assay for creatinine. Patient collected second urine voided between 6 and 9 am from day of clinic visit and day before clinic visit at Months 3, 6, 12 &amp; 24.</description>
          <population>ITT</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="642"/>
                <count group_id="O2" value="650"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-49.45" lower_limit="-53.16" upper_limit="-45.74"/>
                    <measurement group_id="O2" value="-46.62" lower_limit="-50.21" upper_limit="-43.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.83</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.45</ci_lower_limit>
            <ci_upper_limit>0.80</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Serum Type-1 Collagen Cross-linked C-telopeptide (CTX) at Month 6, ITT Population</title>
        <description>ng / mL = nanograms / milliliter. Assayed by electrochemiluminescent immunoassay.</description>
        <time_frame>Baseline to Month 6</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>5 mg Risedronate</title>
            <description>5 mg risedronate tablet, once daily for 2 years</description>
          </group>
          <group group_id="O2">
            <title>150 mg Risedronate</title>
            <description>150 mg risedronate taken once a month for 2 years</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Serum Type-1 Collagen Cross-linked C-telopeptide (CTX) at Month 6, ITT Population</title>
          <description>ng / mL = nanograms / milliliter. Assayed by electrochemiluminescent immunoassay.</description>
          <population>ITT</population>
          <units>ng / mL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="642"/>
                <count group_id="O2" value="650"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.36" lower_limit="-0.39" upper_limit="-0.33"/>
                    <measurement group_id="O2" value="-0.34" lower_limit="-0.37" upper_limit="-0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.05</ci_lower_limit>
            <ci_upper_limit>0.00</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Serum CTX at Month 6, ITT Population</title>
        <description>Assayed by electrochemiluminescent immunoassay.</description>
        <time_frame>Baseline to Month 6</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>5 mg Risedronate</title>
            <description>5 mg risedronate tablet, once daily for 2 years</description>
          </group>
          <group group_id="O2">
            <title>150 mg Risedronate</title>
            <description>150 mg risedronate taken once a month for 2 years</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Serum CTX at Month 6, ITT Population</title>
          <description>Assayed by electrochemiluminescent immunoassay.</description>
          <population>ITT</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="642"/>
                <count group_id="O2" value="650"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-57.79" lower_limit="-61.73" upper_limit="-53.84"/>
                    <measurement group_id="O2" value="-53.62" lower_limit="-57.54" upper_limit="-49.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-4.17</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.98</ci_lower_limit>
            <ci_upper_limit>-0.36</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Serum CTX at Month 24, ITT Population</title>
        <description>Assayed by electrochemiluminescent immunoassay.</description>
        <time_frame>Baseline to Month 24</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>5 mg Risedronate</title>
            <description>5 mg risedronate tablet, once daily for 2 years</description>
          </group>
          <group group_id="O2">
            <title>150 mg Risedronate</title>
            <description>150 mg risedronate taken once a month for 2 years</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Serum CTX at Month 24, ITT Population</title>
          <description>Assayed by electrochemiluminescent immunoassay.</description>
          <population>ITT</population>
          <units>ng / mL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="642"/>
                <count group_id="O2" value="650"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.22" lower_limit="-0.26" upper_limit="-0.19"/>
                    <measurement group_id="O2" value="-0.20" lower_limit="-0.23" upper_limit="-0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.06</ci_lower_limit>
            <ci_upper_limit>0.01</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Serum CTX at Month 24, ITT Population</title>
        <description>Assayed by electrochemiluminescent immunoassay.</description>
        <time_frame>Baseline to Month 24</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>5 mg Risedronate</title>
            <description>5 mg risedronate tablet, once daily for 2 years</description>
          </group>
          <group group_id="O2">
            <title>150 mg Risedronate</title>
            <description>150 mg risedronate taken once a month for 2 years</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Serum CTX at Month 24, ITT Population</title>
          <description>Assayed by electrochemiluminescent immunoassay.</description>
          <population>ITT</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="642"/>
                <count group_id="O2" value="650"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.33" lower_limit="-35.82" upper_limit="-22.84"/>
                    <measurement group_id="O2" value="-23.63" lower_limit="-29.94" upper_limit="-17.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-5.69</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.04</ci_lower_limit>
            <ci_upper_limit>0.66</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Serum Bone-specific Alkaline Phosphatase (BAP) at Month 6, ITT Population</title>
        <description>ug / L = micrograms per liter, Assayed by ELISA (enzyme-linked immunosorbent assay)</description>
        <time_frame>Baseline to Month 6</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>5 mg Risedronate</title>
            <description>5 mg risedronate tablet, once daily for 2 years</description>
          </group>
          <group group_id="O2">
            <title>150 mg Risedronate</title>
            <description>150 mg risedronate taken once a month for 2 years</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Serum Bone-specific Alkaline Phosphatase (BAP) at Month 6, ITT Population</title>
          <description>ug / L = micrograms per liter, Assayed by ELISA (enzyme-linked immunosorbent assay)</description>
          <population>ITT</population>
          <units>ug / L</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="642"/>
                <count group_id="O2" value="650"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.31" lower_limit="-5.79" upper_limit="-4.83"/>
                    <measurement group_id="O2" value="-5.48" lower_limit="-5.96" upper_limit="-5.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.17</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.29</ci_lower_limit>
            <ci_upper_limit>0.64</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Serum BAP at Month 6, ITT Population</title>
        <description>Assayed by ELISA (enzyme-linked immunosorbent assay)</description>
        <time_frame>Baseline to Month 6</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>5 mg Risedronate</title>
            <description>5 mg risedronate tablet, once daily for 2 years</description>
          </group>
          <group group_id="O2">
            <title>150 mg Risedronate</title>
            <description>150 mg risedronate taken once a month for 2 years</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Serum BAP at Month 6, ITT Population</title>
          <description>Assayed by ELISA (enzyme-linked immunosorbent assay)</description>
          <population>ITT</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="642"/>
                <count group_id="O2" value="650"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-33.34" lower_limit="-35.58" upper_limit="-31.11"/>
                    <measurement group_id="O2" value="-34.66" lower_limit="-36.88" upper_limit="-32.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.31</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.85</ci_lower_limit>
            <ci_upper_limit>3.48</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Serum BAP at Month 24, ITT Population</title>
        <description>Assayed by ELISA (enzyme-linked immunosorbent assay)</description>
        <time_frame>Baseline to Month 24</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>5 mg Risedronate</title>
            <description>5 mg risedronate tablet, once daily for 2 years</description>
          </group>
          <group group_id="O2">
            <title>150 mg Risedronate</title>
            <description>150 mg risedronate taken once a month for 2 years</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Serum BAP at Month 24, ITT Population</title>
          <description>Assayed by ELISA (enzyme-linked immunosorbent assay)</description>
          <population>ITT</population>
          <units>ug / L</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="642"/>
                <count group_id="O2" value="650"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.10" lower_limit="-4.69" upper_limit="-3.52"/>
                    <measurement group_id="O2" value="-4.22" lower_limit="-4.79" upper_limit="-3.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.45</ci_lower_limit>
            <ci_upper_limit>0.70</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Serum BAP at Month 24, ITT Population</title>
        <description>Assayed by ELISA (enzyme-linked immunosorbent assay)</description>
        <time_frame>Baseline to Month 24</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>5 mg Risedronate</title>
            <description>5 mg risedronate tablet, once daily for 2 years</description>
          </group>
          <group group_id="O2">
            <title>150 mg Risedronate</title>
            <description>150 mg risedronate taken once a month for 2 years</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Serum BAP at Month 24, ITT Population</title>
          <description>Assayed by ELISA (enzyme-linked immunosorbent assay)</description>
          <population>ITT</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="642"/>
                <count group_id="O2" value="650"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.84" lower_limit="-29.10" upper_limit="-22.57"/>
                    <measurement group_id="O2" value="-25.07" lower_limit="-28.25" upper_limit="-21.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.77</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.96</ci_lower_limit>
            <ci_upper_limit>2.43</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With New Vertebral Fracture at Month 12, ITT Population</title>
        <description>At least 1 new fractured vertebra</description>
        <time_frame>Baseline to Month 12</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>5 mg Risedronate</title>
            <description>5 mg risedronate tablet, once daily for 2 years</description>
          </group>
          <group group_id="O2">
            <title>150 mg Risedronate</title>
            <description>150 mg risedronate taken once a month for 2 years</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With New Vertebral Fracture at Month 12, ITT Population</title>
          <description>At least 1 new fractured vertebra</description>
          <population>ITT</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="642"/>
                <count group_id="O2" value="650"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.0000</p_value>
            <method>Fisher Exact</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.96</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.36</ci_lower_limit>
            <ci_upper_limit>2.54</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With New Vertebral Fracture at Month 24, ITT Population</title>
        <description>At least 1 new fractured vertebra</description>
        <time_frame>Baseline to Month 24</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>5 mg Risedronate</title>
            <description>5 mg risedronate tablet, once daily for 2 years</description>
          </group>
          <group group_id="O2">
            <title>150 mg Risedronate</title>
            <description>150 mg risedronate taken once a month for 2 years</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With New Vertebral Fracture at Month 24, ITT Population</title>
          <description>At least 1 new fractured vertebra</description>
          <population>ITT</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="642"/>
                <count group_id="O2" value="650"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.0000</p_value>
            <method>Fisher Exact</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.98</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.47</ci_lower_limit>
            <ci_upper_limit>2.03</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>17 Oct '05 thru 18 Mar '08</time_frame>
      <group_list>
        <group group_id="E1">
          <title>5 mg Risedronate</title>
          <description>5 mg risedronate tablet, once daily for 2 years</description>
        </group>
        <group group_id="E2">
          <title>150 mg Risedronate</title>
          <description>150 mg risedronate taken once a month for 2 years</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (11.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="642"/>
                <counts group_id="E2" subjects_affected="77" subjects_at_risk="650"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile Neutropenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="642"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="642"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="642"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="650"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial Ischaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="642"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Acute Coronary Syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="642"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Angina Unstable</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="642"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Angina Pectoris</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="642"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="642"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="642"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Congestive Cardiomyopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="642"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Hypertrophic Cardiomyopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="642"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Coronary Artery Disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="642"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Aortic Valve Incompetence</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="642"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Cardiac Failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="642"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Cardiac Arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="642"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="650"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="642"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="650"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blindness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="642"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="642"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="650"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pancreatitis Acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="642"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="642"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Erosive Duodenitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="642"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="642"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="642"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Intestinal Prolapse</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="642"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Gastritis Erosive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="642"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Subileus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="642"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Large Intestine Perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="642"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Lower Gastrointestinal Haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="642"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Umbilical Hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="642"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="642"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Hepatic Cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="642"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="642"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Bile Duct Stone</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="642"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="650"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="642"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="642"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="650"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug Hypersensitivity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="642"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="650"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="642"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="642"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="642"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="642"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="642"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Postoperative Abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="642"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Respiratory Tract Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="642"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="642"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="642"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Toxoplasmosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="642"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Chronic Sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="642"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="642"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Filariasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="642"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Staphylococcal Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="642"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="642"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Lymphangitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="642"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="650"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Patella Fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="642"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Femur Fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="642"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Fibula Fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="642"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Tibia Fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="642"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Hip Fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="642"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Hand Fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="642"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Humerus Fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="642"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Radius Fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="642"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Wrist Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="642"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Road Traffic Accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="642"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="642"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Head Injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="642"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Spinal Compression Fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="642"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Adbominal Pain Upper</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="642"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="650"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="642"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Diabetes Mellitus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="642"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="642"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="642"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="650"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Polyarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="642"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Eosinophilic Fasciitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="642"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Chondrocalcinosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="642"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Foot Deformity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="642"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Rheumatoid Arthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="642"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="642"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="642"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="650"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast Cancer</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="642"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Benign Neoplasm of Thyroid Gland</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="642"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Thyroid Adenoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="642"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>B-cell lymphoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="642"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Fibroadenoma of Breast</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="642"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Cerebellar Tumor</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="642"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Lung Adenocarcinoma Stage II</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="642"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Lung Neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="642"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Colon Cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="642"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Colorectal Cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="642"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Parathyroid Tumour Benign</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="642"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Acute Myeloid Leukaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="642"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Metastases to Lymph Nodes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="642"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Renal Cell Carcinoma Stage Unspecified</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="642"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="650"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular Accident</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="642"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Ischaemic Stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="642"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Carotid Artery Stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="642"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Vertebrobasilar Insufficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="642"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Loss of Consciousness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="642"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="642"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Transient Ischaemic Attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="642"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Dementia Alzheimer's Type</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="642"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Facial Palsy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="642"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="642"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Lumbar Radiculopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="642"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Cubital Tunnel Syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="642"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="642"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="642"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Parkinson's Disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="642"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="650"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Major Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="642"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="650"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Bladder Prolapse</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="642"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="642"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Urethral Stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="642"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="642"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Calculus Urinary</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="642"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="650"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vaginal Prolapse</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="642"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Colpocele</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="642"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Rectocele</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="642"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Cystocele</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="642"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Cervical Dysplasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="642"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="650"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthmatic Crisis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="642"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Chronic Obstructive Pulmonary Disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="642"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Pulmonary Oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="642"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="642"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Lung Disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="642"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="650"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="642"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Pemphigoid</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="642"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Drug Eruption</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="642"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="650"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertensive Emergency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="642"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Aortic Dilatation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="642"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Varicose Vein</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="642"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Cardiovascular Insufficiency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="642"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="650"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA (11.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="554" subjects_at_risk="642"/>
                <counts group_id="E2" subjects_affected="578" subjects_at_risk="650"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="642"/>
                <counts group_id="E2" events="19" subjects_affected="17" subjects_at_risk="650"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="642"/>
                <counts group_id="E2" events="19" subjects_affected="16" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="642"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="650"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrrhoea</sub_title>
                <counts group_id="E1" events="49" subjects_affected="43" subjects_at_risk="642"/>
                <counts group_id="E2" events="95" subjects_affected="69" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Upper</sub_title>
                <counts group_id="E1" events="65" subjects_affected="51" subjects_at_risk="642"/>
                <counts group_id="E2" events="74" subjects_affected="62" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="61" subjects_affected="52" subjects_at_risk="642"/>
                <counts group_id="E2" events="56" subjects_affected="47" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="41" subjects_affected="37" subjects_at_risk="642"/>
                <counts group_id="E2" events="52" subjects_affected="44" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="56" subjects_affected="53" subjects_at_risk="642"/>
                <counts group_id="E2" events="52" subjects_affected="43" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="36" subjects_affected="32" subjects_at_risk="642"/>
                <counts group_id="E2" events="41" subjects_affected="36" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="36" subjects_affected="32" subjects_at_risk="642"/>
                <counts group_id="E2" events="48" subjects_affected="31" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="21" subjects_affected="19" subjects_at_risk="642"/>
                <counts group_id="E2" events="26" subjects_affected="24" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Abdominal Distention</sub_title>
                <counts group_id="E1" events="18" subjects_affected="16" subjects_at_risk="642"/>
                <counts group_id="E2" events="24" subjects_affected="19" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="642"/>
                <counts group_id="E2" events="21" subjects_affected="18" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Hyperchlorhydria</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="642"/>
                <counts group_id="E2" events="18" subjects_affected="18" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Gastroesophageal Reflux Disease</sub_title>
                <counts group_id="E1" events="14" subjects_affected="13" subjects_at_risk="642"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Hiatus Hernia</sub_title>
                <counts group_id="E1" events="20" subjects_affected="20" subjects_at_risk="642"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Gastritis erosive</sub_title>
                <counts group_id="E1" events="15" subjects_affected="14" subjects_at_risk="642"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="642"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="650"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="19" subjects_affected="18" subjects_at_risk="642"/>
                <counts group_id="E2" events="24" subjects_affected="23" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="642"/>
                <counts group_id="E2" events="21" subjects_affected="21" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Oedema Peripheral</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="642"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="642"/>
                <counts group_id="E2" events="25" subjects_affected="13" subjects_at_risk="650"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="62" subjects_affected="57" subjects_at_risk="642"/>
                <counts group_id="E2" events="112" subjects_affected="94" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="76" subjects_affected="62" subjects_at_risk="642"/>
                <counts group_id="E2" events="86" subjects_affected="70" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="58" subjects_affected="50" subjects_at_risk="642"/>
                <counts group_id="E2" events="83" subjects_affected="61" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="76" subjects_affected="68" subjects_at_risk="642"/>
                <counts group_id="E2" events="74" subjects_affected="57" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="24" subjects_affected="21" subjects_at_risk="642"/>
                <counts group_id="E2" events="25" subjects_affected="24" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="642"/>
                <counts group_id="E2" events="24" subjects_affected="18" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="7" subjects_at_risk="642"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Tooth Infection</sub_title>
                <counts group_id="E1" events="14" subjects_affected="13" subjects_at_risk="642"/>
                <counts group_id="E2" events="16" subjects_affected="11" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="22" subjects_affected="19" subjects_at_risk="642"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="642"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="15" subjects_affected="14" subjects_at_risk="642"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="650"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="57" subjects_affected="45" subjects_at_risk="642"/>
                <counts group_id="E2" events="66" subjects_affected="57" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="26" subjects_affected="19" subjects_at_risk="642"/>
                <counts group_id="E2" events="24" subjects_affected="17" subjects_at_risk="650"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="642"/>
                <counts group_id="E2" events="22" subjects_affected="22" subjects_at_risk="650"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="81" subjects_affected="68" subjects_at_risk="642"/>
                <counts group_id="E2" events="76" subjects_affected="65" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="87" subjects_affected="80" subjects_at_risk="642"/>
                <counts group_id="E2" events="73" subjects_affected="65" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="37" subjects_affected="35" subjects_at_risk="642"/>
                <counts group_id="E2" events="50" subjects_affected="45" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Pain in Extremity</sub_title>
                <counts group_id="E1" events="28" subjects_affected="24" subjects_at_risk="642"/>
                <counts group_id="E2" events="31" subjects_affected="29" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Muscle Spasms</sub_title>
                <counts group_id="E1" events="15" subjects_affected="14" subjects_at_risk="642"/>
                <counts group_id="E2" events="23" subjects_affected="22" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Musculoskeletal Pain</sub_title>
                <counts group_id="E1" events="21" subjects_affected="20" subjects_at_risk="642"/>
                <counts group_id="E2" events="22" subjects_affected="20" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="642"/>
                <counts group_id="E2" events="19" subjects_affected="17" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" events="17" subjects_affected="16" subjects_at_risk="642"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Neck Pain</sub_title>
                <counts group_id="E1" events="20" subjects_affected="19" subjects_at_risk="642"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Muscle Contracture</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="642"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="650"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="51" subjects_affected="38" subjects_at_risk="642"/>
                <counts group_id="E2" events="37" subjects_affected="35" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="20" subjects_affected="17" subjects_at_risk="642"/>
                <counts group_id="E2" events="27" subjects_affected="26" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="642"/>
                <counts group_id="E2" events="19" subjects_affected="17" subjects_at_risk="650"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="642"/>
                <counts group_id="E2" events="21" subjects_affected="20" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="642"/>
                <counts group_id="E2" events="18" subjects_affected="18" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="642"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="650"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="22" subjects_affected="20" subjects_at_risk="642"/>
                <counts group_id="E2" events="25" subjects_affected="24" subjects_at_risk="650"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="642"/>
                <counts group_id="E2" events="16" subjects_affected="14" subjects_at_risk="650"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="22" subjects_affected="19" subjects_at_risk="642"/>
                <counts group_id="E2" events="14" subjects_affected="10" subjects_at_risk="650"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="53" subjects_affected="49" subjects_at_risk="642"/>
                <counts group_id="E2" events="55" subjects_affected="52" subjects_at_risk="650"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Grexan Wulff, Manager Regulatory Affairs</name_or_title>
      <organization>Warner Chilcott</organization>
      <phone>973-442-3376</phone>
      <email>gwulff@wcrx.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

